Stockscreener 앱 받기
5.29
10.94%
-0.65
시간 외 거래:
5.41
0.12
+2.27%
전일 마감가:
$5.94
열려 있는:
$5.9
하루 거래량:
205.68K
Relative Volume:
0.08
시가총액:
$10.31M
수익:
$7.06M
순이익/손실:
$-21.17M
주가수익비율:
-4.4309
EPS:
-1.1939
순현금흐름:
$-28.95M
1주 성능:
+913.22%
1개월 성능:
+1,018%
6개월 성능:
+529.54%
1년 성능:
+204.02%
1일 변동 폭
$4.975
$5.90
1주일 범위
$0.3405
$6.74
52주 변동 폭
$0.1806
$6.74
Curis Inc Stock (CRIS) Company Profile
명칭
Curis Inc
전화
617-503-6500
주소
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
5.29 | 11.58M | 7.06M | -21.17M | -28.95M | -1.1939 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2023-11-17 | 개시 | Truist | Buy |
| 2022-04-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | 개시 | Raymond James | Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2020-07-29 | 개시 | Laidlaw | Buy |
| 2020-07-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-08-11 | 개시 | FBR Capital | Outperform |
| 2015-01-22 | 재확인 | Oppenheimer | Outperform |
| 2015-01-21 | 재확인 | ROTH Capital | Buy |
| 2014-05-09 | 재확인 | Oppenheimer | Outperform |
| 2013-10-02 | 개시 | Robert W. Baird | Outperform |
| 2013-09-30 | 개시 | Chardan Capital Markets | Buy |
| 2012-11-14 | 개시 | Stifel Nicolaus | Hold |
| 2012-01-31 | 재확인 | Brean Murray | Buy |
| 2012-01-31 | 재확인 | Summer Street Research | Buy |
| 2011-12-09 | 개시 | Oppenheimer | Outperform |
| 2011-10-06 | 개시 | Summer Street Research | Buy |
| 2011-09-22 | 개시 | MLV Capital | Buy |
| 2011-03-21 | 재확인 | Brean Murray | Buy |
| 2010-02-26 | 재확인 | Roth Capital | Buy |
| 2010-01-07 | 개시 | Roth Capital | Buy |
모두보기
Curis Inc 주식(CRIS)의 최신 뉴스
Curis stock edges into a thin-day update. - AD HOC NEWS
CRIS Q1 2026 Earnings: Wider Than Expected Loss Sends Shares LowerEarnings Yield Analysis - dars.gov.et
Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia - Moomoo
Curis (CRIS) Advances TakeAim CLL Study with Patient Enrollment Progress - GuruFocus
Curis Achieves Key Milestone in TakeAim CLL Study - Intellectia AI
Curis Consents First Six Patients in TakeAim CLL Study - PR Newswire
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split - AOL.com
Curis Inc outlines oncology pipeline as investors watch funding and trial progress - AD HOC NEWS
Curis Implements 1-for-20 Reverse Stock Split - TipRanks
Curis (NASDAQ: CRIS) sets 1-for-20 reverse split and adjusts equity awards - Stock Titan
Why did Curis (CRIS) stock soar after hours? - MSN
Why Did Curis (CRIS) Stock Soar After Hours? - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Curis (CRIS) schedules reverse stock split and split-adjusted trading - Stock Titan
Curis Stockholders Approve 1-for-20 Reverse Split - TipRanks
Curis (NASDAQ: CRIS) sets 1-for-20 reverse stock split after holder vote - Stock Titan
CRIS Q1 2026 Earnings: Significant Earnings Miss Amid No Reported RevenueEarnings Call Q&A - dars.gov.et
Curis opens 11 sites for emavusertib combo in TakeAim CLL trial - Yahoo Finance
$Curis (CRIS.US)$ cold blooded 🤣 - Moomoo
Curis opens 11 sites for CLL study, shareholders approve stock split - Investing.com South Africa
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
$Curis (CRIS.US)$ 💎 in the rough - Moomoo
Curis (CRIS) Launches Phase 2 CLL Study and Plans Reverse Stock Split - GuruFocus
Curis announces eleven active clinical sites in TakeAim CLL study - TipRanks
Price to sales forward of Curis, Inc. – NASDAQ:CRIS - TradingView
Curis, Inc. Actuals & Estimates (MUN:CUS0) - TradingView
Enterprise value to EBIT forward of Curis, Inc. – NASDAQ:CRIS - TradingView
CUS0 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Curis, Inc. – LS:A3ETJD - TradingView
Curis Shareholders Approve Flexible Reverse Stock Split Authorization - TipRanks
[8-K] CURIS INC Reports Material Event - Stock Titan
Curis (CRIS) EGM 2026 Summary - Quartr
CRIS: Reverse stock split and adjournment proposals were both approved by majority vote - TradingView
Curis Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
Price to earnings forward of Curis, Inc. – NASDAQ:CRIS - TradingView
CRIS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Curis, Inc. – LS:A3ETJD - TradingView
Enterprise value to revenue forward of Curis, Inc. – NASDAQ:CRIS - TradingView
Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk - Yahoo Finance
Curis Inc. (CRIS) Edges Higher: Testing Key Resistance Amid Speculative TradingBreakout Stock Alerts - dars.gov.et
Curis StockAnalyst focus and biotech sector review - AD HOC NEWS
Curis Inc (CRIS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Curis Inc (CRIS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curis Inc (CRIS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curis Inc (CRIS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Curis Inc (CRIS) Institutional Confidence - TradingKey
Curis Inc (CRIS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Curis Inc (CRIS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curis Inc Stock (US2312691006): Quarterly earnings keep biotech micro-cap in focus - AD HOC NEWS
Curis Inc (CRIS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):